Board Chairman Sol Barer, PhD, also waived his right to cash compensation altogether as the debt-ridden pharmaceutical giant looks to lessen its $35 billion debt burden.
In late November, Teva outlined a reorganization plan aiming to address the drugmaker’s plummeting revenues and financial commitments. The pay cut is reportedly part of this restructuring plan.
More articles on supply chain:
Mylan reaffirms $1B share buyback plan
FDA: IV fluid shortage exacerbated by hurricane damage to Puerto Rico is expected to improve
Stanford Blood Center faces critical shortage of blood, notes the flu is keeping potential donors away
